- ISIN
- US78397T1034
- CUSIP
- 78397T103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 9, 2021
Highlights
- Market Cap
- $210.49M
- Enterprise Value
- $197.06M
- EPS (TTM)
- -$0.01
- Gross Profit (TTM)
- -$2.35M
- EBITDA (TTM)
- $994.59K
- Year Range
- $1.67 - $6.60
- Target Price
- $8.50
- ROA (TTM)
- -0.16%
- ROE (TTM)
- -0.18%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SABS Performance Chart
SAB Biotherapeutics, Inc. (SABS) is up 5.1% since the beginning of the year. At $4 per share, SABS is trading 40.5% below its 52-week high of $7. Investors who bought $1,000 worth of SABS shares 5 years ago would now be looking at an investment worth $39.
Loading charts...
Returns By Period
SAB Biotherapeutics, Inc. (SABS) has returned 5.08% so far this year and 119.55% over the past 12 months.
SAB Biotherapeutics, Inc.
- 1D
- -1.75%
- 1M
- 0.77%
- YTD
- 5.08%
- 6M
- 2.34%
- 1Y
- 119.55%
- 3Y*
- -21.42%
- 5Y*
- -47.61%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SABS Monthly Returns History
Based on dividend-adjusted daily data since Feb 9, 2021, SABS's average daily return is -0.02%, while the average monthly return is -2.03%.
Historically, 37% of months were positive and 63% were negative. The best month was Apr 2023 with a return of +104.2%, while the worst month was Dec 2022 at -45.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 9 months.
On a daily basis, SABS closed higher 44% of trading days. The best single day was Apr 13, 2023 with a return of +99.7%, while the worst single day was Jan 28, 2025 at -52.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 17.38% | -6.61% | -6.59% | -2.35% | -3.74% | 9.17% | 5.08% | ||||||
| 2025 | -42.28% | -21.92% | -20.47% | 25.00% | 13.53% | -9.07% | 7.12% | 10.64% | -3.37% | 61.69% | 21.54% | -5.32% | -1.43% |
| 2024 | -12.73% | -25.67% | 1.79% | -5.51% | -38.46% | 17.42% | -10.48% | 5.94% | -8.16% | 20.74% | -10.43% | 29.94% | -44.81% |
| 2023 | 15.17% | -4.33% | -32.31% | 104.16% | -0.92% | -6.74% | -2.41% | -11.11% | -12.50% | 58.71% | -2.79% | -29.27% | 16.55% |
| 2022 | -25.61% | -14.63% | -24.19% | -33.51% | -21.60% | -26.02% | -25.52% | -35.18% | 0.13% | 28.39% | 20.00% | -45.38% | -92.45% |
| 2021 | -1.37% | -2.58% | 1.32% | -0.30% | 0.43% | -0.53% | 0.61% | 1.10% | -21.53% | 37.67% | -28.28% | -23.58% |
Benchmark Metrics
SAB Biotherapeutics, Inc. has an annualized alpha of -14.11%, beta of 0.72, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 09, 2021.
- This stock participated in 156.39% of S&P 500 Index downside but only -64.46% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -14.11%
- Beta
- 0.72
- R²
- 0.01
- Upside Capture
- -64.46%
- Downside Capture
- 156.39%
Return for Risk
Risk / Return Rank
SABS ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for SAB Biotherapeutics, Inc. (SABS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SABS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.62 | ||
| Sortino ratioReturn per unit of downside risk | -0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.37 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 3.56 | 2.78 | +0.77 |
| Martin ratioReturn relative to average drawdown | 7.65 | 12.44 | -4.79 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the SAB Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the SAB Biotherapeutics, Inc. was 99.01%, occurring on Apr 7, 2025. The portfolio has not yet recovered.
The current SAB Biotherapeutics, Inc. drawdown is 96.50%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.01%Apr 2025 | 3y 4mo | — | 4y 6moDec 2021 - now |
2021 bear market2021 | -30.28%Oct 2021 | 6d | 23d | 29dOct 2021 - Nov 2021 |
2021 bear market2021 | -23.01%Nov 2021 | 5d | 8d | 13dNov 2021 - Dec 2021 |
2021 pullback2021 | -6.07%Mar 2021 | 1mo 4d | 6mo 27d | 8mo 1dFeb 2021 - Oct 2021 |
2021 pullback2021 | -0.83%Feb 2021 | 2d | 5d | 7dFeb 2021 - Feb 2021 |
Drawdown Indicators
| SABS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.01% | -56.78% | -42.23% |
Max Drawdown (1Y)Largest decline over 1 year | -33.80% | -9.10% | -24.70% |
Max Drawdown (3Y)Largest decline over 3 years | -88.96% | -18.90% | -70.06% |
Max Drawdown (5Y)Largest decline over 5 years | -99.01% | -25.43% | -73.58% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -96.50% | -1.80% | -94.70% |
Average DrawdownAverage peak-to-trough decline | -78.14% | -10.71% | -67.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.69% | 2.03% | +13.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of SAB Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how SAB Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SABS in comparison with other companies in the Biotechnology industry. Currently, SABS has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SABS
Add SAB Biotherapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SABS